On April 18, 2022 Helix BioPharma Corp. (TSX: "HBP") ("Helix" or the "Company’), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, reported that Artur Gabor has been appointed as the Company’s Chief Executive Officer with immediate effect (Press release, Helix BioPharma, APR 18, 2022, View Source [SID1234612485]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!